AnalystBook Research · Company Intelligence

Cinemark Holdings, Inc.

CNKNYSE

Built from Cinemark Holdings, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Cinemark grew sales slightly, but net income fell hard and cash-flow fields were absent.

The read at a glance✓ Audited against SEC data
  • Business mixUS, international, admissions, concessionsNote
  • Revenue$3.12B, +2.1%OK
  • Net income$0.14B, -55.4%Watch
  • Cash flowFCF not availableWatch
  • MarginNet margin 4.4%, -572 bpsWatch
  • Altman/Beneish/EQDistress Z; M flag; EQ safeWatch
  • Insiders0 purchases / 4 salesWatch

Business

Cinemark is a movie-theater exhibitor with US and international theaters, admissions, concessions, and other theater revenue streams.

Where the revenue comes from

Fiscal 2025, as Cinemark Holdings, Inc. reports it. History and quarterly detail are in the app.

  • Admission$1.5B
  • Admissions Revenue$1.5B
  • Concessions$1.2B
  • Other Revenues$343.1M
  • Other Revenue$190.9M

Leadership changes

From Cinemark Holdings, Inc.'s own filings, the day they're filed.

  • Accrued Entitlements · departure

Latest filings

  • 8-K · Company announcement2026-08-12
  • 10-Q · Quarterly report2026-07-30
  • 8-K · Company announcement2026-07-30
  • 8-K · Company announcement2026-05-14
  • 8-K · Company announcement2026-05-12
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Cinemark Holdings, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.